Cassava Sciences Completes Interim Safety Review Of Oral Simufilam On-Going Phase 3 Trials
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences announced that an independent Data and Safety Monitoring Board (DSMB) has completed an interim safety review of its oral Simufilam in ongoing Phase 3 trials. The DSMB recommended that the trials continue as planned without modifications. Final clinical safety data will be available at the end of the Phase 3 program.
September 24, 2024 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cassava Sciences' oral Simufilam Phase 3 trials have been reviewed by an independent DSMB, which recommended the trials continue without modifications. This is a positive development for the company as it progresses towards final safety data.
The DSMB's recommendation to continue the trials without modifications suggests that there are no significant safety concerns at this stage, which is a positive indicator for the success of the trials. This could boost investor confidence in Cassava Sciences, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100